UA78489C2 - Monoclonal antibody, chimeric antibody, completely humanized antibody, antibody to antiidiotypic antibody or fragment thereof to receptor of lipoproteins of low density (lpld) of human, a method for obtaining and use thereof - Google Patents

Monoclonal antibody, chimeric antibody, completely humanized antibody, antibody to antiidiotypic antibody or fragment thereof to receptor of lipoproteins of low density (lpld) of human, a method for obtaining and use thereof Download PDF

Info

Publication number: UA78489C2
Authority: UA; Ukraine
Prior art keywords: antibody; monoclonal antibody; human; receptor; deposited
Prior art date: 2000-03-13

Application number

UA2002108101A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-13

Filing date

2001-08-03

Publication date

2007-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323933&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA78489(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-13 Priority claimed from IL13502500A external-priority patent/IL135025A0/xx

2001-08-03 Application filed by Applied Research Systems filed Critical Applied Research Systems

2007-04-10 Publication of UA78489C2 publication Critical patent/UA78489C2/uk

Links

239000012634 fragment Substances 0.000 title claims abstract description 22
238000000034 method Methods 0.000 title claims description 50
102000004895 Lipoproteins Human genes 0.000 title abstract description 5
108090001030 Lipoproteins Proteins 0.000 title abstract description 5
241001465754 Metazoa Species 0.000 claims abstract description 9
230000010076 replication Effects 0.000 claims abstract description 8
238000011282 treatment Methods 0.000 claims abstract description 8
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
210000004027 cell Anatomy 0.000 claims description 55
210000004408 hybridoma Anatomy 0.000 claims description 36
108020003175 receptors Proteins 0.000 claims description 26
102000005962 receptors Human genes 0.000 claims description 26
230000003053 immunization Effects 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 13
208000015181 infectious disease Diseases 0.000 claims description 12
108010007622 LDL Lipoproteins Proteins 0.000 claims description 8
102000007330 LDL Lipoproteins Human genes 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
239000000463 material Substances 0.000 claims description 7
241000711549 Hepacivirus C Species 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
108060003951 Immunoglobulin Proteins 0.000 claims description 5
102000018358 immunoglobulin Human genes 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
108010001831 LDL receptors Proteins 0.000 claims description 4
102000000853 LDL receptors Human genes 0.000 claims description 4
210000004698 lymphocyte Anatomy 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 2
210000000683 abdominal cavity Anatomy 0.000 claims description 2
210000000952 spleen Anatomy 0.000 claims description 2
230000029812 viral genome replication Effects 0.000 claims description 2
101000899339 Homo sapiens Lymphoid-specific helicase Proteins 0.000 claims 2
102000046082 human HELLS Human genes 0.000 claims 2
229940126601 medicinal product Drugs 0.000 claims 2
238000009825 accumulation Methods 0.000 claims 1
208000006454 hepatitis Diseases 0.000 claims 1
231100000283 hepatitis Toxicity 0.000 claims 1
238000002649 immunization Methods 0.000 abstract description 13
208000005176 Hepatitis C Diseases 0.000 abstract description 4
241000700605 Viruses Species 0.000 abstract description 3
238000004140 cleaning Methods 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 32
241000699670 Mus sp. Species 0.000 description 29
239000000427 antigen Substances 0.000 description 28
108091007433 antigens Proteins 0.000 description 27
102000036639 antigens Human genes 0.000 description 27
235000018102 proteins Nutrition 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
238000004458 analytical method Methods 0.000 description 18
230000000840 anti-viral effect Effects 0.000 description 18
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
239000000243 solution Substances 0.000 description 17
239000000758 substrate Substances 0.000 description 17
230000027455 binding Effects 0.000 description 15
239000000523 sample Substances 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
229920001213 Polysorbate 20 Polymers 0.000 description 13
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 13
239000007787 solid Substances 0.000 description 13
210000002966 serum Anatomy 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
238000001514 detection method Methods 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000001262 western blot Methods 0.000 description 11
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
210000003494 hepatocyte Anatomy 0.000 description 10
238000011534 incubation Methods 0.000 description 10
239000002609 medium Substances 0.000 description 10
125000000539 amino acid group Chemical group 0.000 description 9
238000003556 assay Methods 0.000 description 9
239000000872 buffer Substances 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000000746 purification Methods 0.000 description 9
239000007790 solid phase Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 8
239000012530 fluid Substances 0.000 description 8
206010003445 Ascites Diseases 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
210000004379 membrane Anatomy 0.000 description 6
229940033663 thimerosal Drugs 0.000 description 6
108010001336 Horseradish Peroxidase Proteins 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
210000003567 ascitic fluid Anatomy 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000011161 development Methods 0.000 description 5
230000004927 fusion Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
238000012216 screening Methods 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000013642 negative control Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
108010028554 LDL Cholesterol Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
244000309464 bull Species 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000013198 immunometric assay Methods 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
239000003446 ligand Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000002245 particle Substances 0.000 description 3
-1 polypropylene Polymers 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000011002 quantification Methods 0.000 description 3
238000004445 quantitative analysis Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000001542 size-exclusion chromatography Methods 0.000 description 3
239000013598 vector Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000851593 Homo sapiens Separin Proteins 0.000 description 2
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 2
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
102100036750 Separin Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
210000004404 adrenal cortex Anatomy 0.000 description 2
210000001691 amnion Anatomy 0.000 description 2
238000005341 cation exchange Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000004590 computer program Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
201000001386 familial hypercholesterolemia Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000002955 isolation Methods 0.000 description 2
108020001756 ligand binding domains Proteins 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
238000005497 microtitration Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000001853 pulsed-field electrophoresis Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000723298 Dicentrarchus labrax Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
208000004605 Persistent Truncus Arteriosus Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
238000004354 ROESY-TOCSY relay Methods 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000690647 Tatia Species 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
208000037258 Truncus arteriosus Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000367327 Xenomys Species 0.000 description 1
229910021536 Zeolite Inorganic materials 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000007720 allelic exclusion Effects 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
238000011948 assay development Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
210000001109 blastomere Anatomy 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000013373 clone screening Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000003235 crystal violet staining Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001378 electrochemiluminescence detection Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000005206 flow analysis Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000011330 nucleic acid test Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940054441 o-phthalaldehyde Drugs 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000010187 selection method Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012764 semi-quantitative analysis Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000029302 virus maturation Effects 0.000 description 1
239000010457 zeolite Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

UA2002108101A 2000-03-13 2001-08-03 Monoclonal antibody, chimeric antibody, completely humanized antibody, antibody to antiidiotypic antibody or fragment thereof to receptor of lipoproteins of low density (lpld) of human, a method for obtaining and use thereof UA78489C2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IL13502500A IL135025A0 (en)	2000-03-13	2000-03-13	Monoclonal antibodies to the human ldl receptor, their production and use
IL13921700A IL139217A0 (en)	2000-03-13	2000-10-23	Monoclonal antibodies to the human ldl receptor, their production and use
PCT/IL2001/000216 WO2001068710A1 (en)	2000-03-13	2001-03-08	Monoclonal antibodies to the human ldl receptor, their production and use

Publications (1)

Publication Number	Publication Date
UA78489C2 true UA78489C2 (en)	2007-04-10

Family

ID=26323933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002108101A UA78489C2 (en)	2000-03-13	2001-08-03	Monoclonal antibody, chimeric antibody, completely humanized antibody, antibody to antiidiotypic antibody or fragment thereof to receptor of lipoproteins of low density (lpld) of human, a method for obtaining and use thereof

Country Status (33)

Country	Link
US (1)	US6849720B2 (sh)
EP (1)	EP1263790B1 (sh)
JP (1)	JP4768193B2 (sh)
KR (1)	KR100882081B1 (sh)
CN (1)	CN1418225B (sh)
AR (1)	AR028518A1 (sh)
AT (1)	ATE362490T1 (sh)
AU (2)	AU4100201A (sh)
BG (1)	BG65762B1 (sh)
BR (1)	BR0109164A (sh)
CA (1)	CA2402593C (sh)
CY (1)	CY1108020T1 (sh)
CZ (1)	CZ20023098A3 (sh)
DE (1)	DE60128452T2 (sh)
DK (1)	DK1263790T3 (sh)
EA (1)	EA007494B1 (sh)
EE (1)	EE200200517A (sh)
ES (1)	ES2282238T3 (sh)
HK (1)	HK1055750A1 (sh)
HR (1)	HRP20020704B1 (sh)
HU (1)	HU226194B1 (sh)
IL (2)	IL139217A0 (sh)
MX (1)	MXPA02009091A (sh)
NO (1)	NO330904B1 (sh)
NZ (1)	NZ520944A (sh)
PL (1)	PL206041B1 (sh)
PT (1)	PT1263790E (sh)
RS (1)	RS51406B (sh)
SI (1)	SI1263790T1 (sh)
SK (1)	SK287348B6 (sh)
UA (1)	UA78489C2 (sh)
WO (1)	WO2001068710A1 (sh)
ZA (1)	ZA200206654B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0114629D0 (en) *	2001-06-15	2001-08-08	Pfizer Ltd	Method
US7598046B2 (en)	2003-06-19	2009-10-06	Laboratories Serono Sa	Use of prion conversion modulating agents
FR2889532B1 (fr) *	2005-08-03	2007-10-12	Lab Francais Du Fractionnement	Anticorps diriges contre le recepteur du ldl
FR2889533B1 (fr) *	2005-08-03	2007-10-12	Lab Francais Du Fractionnement	Anticorps diriges contre le recepteur du ldl
EP1991869A2 (en) *	2006-02-17	2008-11-19	Paolo La Colla	Methods for the diagnosis of proliferative and/or conformational diseases
FR2910896B1 (fr) *	2006-12-29	2012-11-16	Lab Francais Du Fractionnement	Anticorps monoclonal dirige contre le recepteur humain des ldl
IL182956A0 (en)	2007-05-03	2008-01-20	Yeda Res & Dev	Glycan modified soluble receptors and binding proteins and their use
IL188628A0 (en) *	2008-01-07	2008-12-29	Yeda Res & Dev	Use of soluble ldl-r for viral hepatitis
GB0922377D0 (en) *	2009-12-22	2010-02-03	Arab Gulf University The	Mutant LDL receptor
BR112012029881A2 (pt)	2010-05-25	2019-09-24	Inserm (Institut National De La Santé De La Recherche Médicale)	combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv
WO2013024155A1 (en)	2011-08-17	2013-02-21	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024157A2 (en)	2011-08-17	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024156A2 (en)	2011-08-17	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
CN103111270B (zh) *	2013-02-26	2015-06-10	王业富	一种乙型肝炎抗原蛋白的吸附材料及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182364A (en) *	1990-02-26	1993-01-26	The Scripps Research Institute	Polypeptide analogs of apolipoprotein E
US5496926A (en) *	1992-01-19	1996-03-05	Yeda Research And Development Co. Ltd.	Process of preparing a soluble LDL receptor
US5945308A (en) *	1998-04-03	1999-08-31	Incyte Pharmaceuticals, Inc.	Human oxidized LDL receptor
JP2000279174A (ja) *	1999-03-30	2000-10-10	Bml Inc	ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法

2000
- 2000-10-23 IL IL13921700A patent/IL139217A0/xx unknown
2001
- 2001-03-08 AT AT01912086T patent/ATE362490T1/de active
- 2001-03-08 WO PCT/IL2001/000216 patent/WO2001068710A1/en active IP Right Grant
- 2001-03-08 DE DE60128452T patent/DE60128452T2/de not_active Expired - Lifetime
- 2001-03-08 US US10/221,679 patent/US6849720B2/en not_active Expired - Fee Related
- 2001-03-08 HU HU0300142A patent/HU226194B1/hu not_active IP Right Cessation
- 2001-03-08 CZ CZ20023098A patent/CZ20023098A3/cs unknown
- 2001-03-08 AU AU4100201A patent/AU4100201A/xx active Pending
- 2001-03-08 RS YUP-686/02A patent/RS51406B/sr unknown
- 2001-03-08 EP EP01912086A patent/EP1263790B1/en not_active Expired - Lifetime
- 2001-03-08 KR KR1020027011767A patent/KR100882081B1/ko not_active IP Right Cessation
- 2001-03-08 IL IL15171301A patent/IL151713A0/xx not_active IP Right Cessation
- 2001-03-08 PL PL358381A patent/PL206041B1/pl unknown
- 2001-03-08 PT PT01912086T patent/PT1263790E/pt unknown
- 2001-03-08 JP JP2001567800A patent/JP4768193B2/ja not_active Expired - Fee Related
- 2001-03-08 EE EEP200200517A patent/EE200200517A/xx unknown
- 2001-03-08 AU AU2001241002A patent/AU2001241002B8/en not_active Ceased
- 2001-03-08 CN CN018065740A patent/CN1418225B/zh not_active Expired - Fee Related
- 2001-03-08 MX MXPA02009091A patent/MXPA02009091A/es active IP Right Grant
- 2001-03-08 ES ES01912086T patent/ES2282238T3/es not_active Expired - Lifetime
- 2001-03-08 CA CA2402593A patent/CA2402593C/en not_active Expired - Fee Related
- 2001-03-08 SI SI200130736T patent/SI1263790T1/sl unknown
- 2001-03-08 NZ NZ520944A patent/NZ520944A/en not_active IP Right Cessation
- 2001-03-08 BR BR0109164-6A patent/BR0109164A/pt not_active Application Discontinuation
- 2001-03-08 SK SK1312-2002A patent/SK287348B6/sk not_active IP Right Cessation
- 2001-03-08 DK DK01912086T patent/DK1263790T3/da active
- 2001-03-08 EA EA200200974A patent/EA007494B1/ru not_active IP Right Cessation
- 2001-03-12 AR ARP010101148A patent/AR028518A1/es active IP Right Grant
- 2001-08-03 UA UA2002108101A patent/UA78489C2/uk unknown
2002
- 2002-08-20 ZA ZA200206654A patent/ZA200206654B/en unknown
- 2002-08-28 HR HR20020704A patent/HRP20020704B1/xx not_active IP Right Cessation
- 2002-09-04 NO NO20024223A patent/NO330904B1/no not_active IP Right Cessation
- 2002-09-05 BG BG107063A patent/BG65762B1/bg unknown
2003
- 2003-11-11 HK HK03108147.2A patent/HK1055750A1/xx not_active IP Right Cessation
2007
- 2007-07-13 CY CY20071100939T patent/CY1108020T1/el unknown

Also Published As

Publication number	Publication date
HUP0300142A2 (hu)	2003-06-28
PL206041B1 (pl)	2010-06-30
DK1263790T3 (da)	2007-07-02
YU68602A (sh)	2006-03-03
RS51406B (sr)	2011-02-28
AR028518A1 (es)	2003-05-14
ZA200206654B (en)	2003-10-20
NO330904B1 (no)	2011-08-15
KR100882081B1 (ko)	2009-02-10
ES2282238T3 (es)	2007-10-16
ATE362490T1 (de)	2007-06-15
BG107063A (bg)	2003-05-30
AU4100201A (en)	2001-09-24
NO20024223D0 (no)	2002-09-04
HK1055750A1 (en)	2004-01-21
NO20024223L (no)	2002-10-24
JP4768193B2 (ja)	2011-09-07
CA2402593C (en)	2012-07-03
SK13122002A3 (sk)	2003-04-01
EA200200974A1 (ru)	2003-02-27
WO2001068710A1 (en)	2001-09-20
BG65762B1 (bg)	2009-10-30
EE200200517A (et)	2004-02-16
IL151713A0 (en)	2003-04-10
CA2402593A1 (en)	2001-09-20
NZ520944A (en)	2004-04-30
HU226194B1 (hu)	2008-06-30
US20030186343A1 (en)	2003-10-02
KR20020089384A (ko)	2002-11-29
CN1418225B (zh)	2012-04-18
EA007494B1 (ru)	2006-10-27
BR0109164A (pt)	2002-11-26
AU2001241002B8 (en)	2006-05-04
SI1263790T1 (sl)	2007-10-31
MXPA02009091A (es)	2005-06-20
JP2004506603A (ja)	2004-03-04
DE60128452D1 (de)	2007-06-28
IL139217A0 (en)	2001-11-25
HRP20020704A2 (en)	2004-12-31
PL358381A1 (en)	2004-08-09
CY1108020T1 (el)	2013-09-04
US6849720B2 (en)	2005-02-01
SK287348B6 (sk)	2010-08-09
CZ20023098A3 (cs)	2003-02-12
HRP20020704B1 (en)	2011-01-31
DE60128452T2 (de)	2007-09-13
CN1418225A (zh)	2003-05-14
EP1263790A1 (en)	2002-12-11
EP1263790B1 (en)	2007-05-16
AU2001241002B2 (en)	2006-04-06
PT1263790E (pt)	2007-06-01
HUP0300142A3 (en)	2005-07-28

Publication	Publication Date	Title
UA78489C2 (en)	2007-04-10	Monoclonal antibody, chimeric antibody, completely humanized antibody, antibody to antiidiotypic antibody or fragment thereof to receptor of lipoproteins of low density (lpld) of human, a method for obtaining and use thereof
WO1998022510A9 (en)	1998-12-23	Methods for the production of chicken monoclonal antibodies
WO1998022510A2 (en)	1998-05-28	Methods for the production of chicken monoclonal antibodies
AU2001241002A1 (en)	2001-12-06	Monoclonal antibodies to the human LDL receptor, their production and use
MXPA06003886A (es)	2006-08-11	Reactivos de enlace de inmunoglobulina naturales y metodos de fabricacion y uso de los mismos.
CA1231067A (en)	1988-01-05	Monoclonal antibody to peroxidase and hybridoma producing it
JP3288716B2 (ja)	2002-06-04	ヒト接着分子オクルディン
JPH0789998A (ja)	1995-04-04	抗ミクロシスチンモノクローナル抗体およびそれを産生するハイブリドーマ
EP3998280A1 (en)	2022-05-18	Hybridoma and method for producing same, and monoclonal antibody and method for producing same
JP3472664B2 (ja)	2003-12-02	抗繊維芽細胞増殖因子５モノクローナル抗体
CN114213542B (zh)	2023-06-23	Cps-i抗体及其用途
JP3522877B2 (ja)	2004-04-26	抗チロシナーゼモノクローナル抗体Ｆ（ａｂ’）２フラグメント
KR20240097988A (ko)	2024-06-27	신규한 일본뇌염 바이러스 항원과 일본뇌염 특이 항체 및 이의 용도
KR0140365B1 (ko)	1998-06-15	콜레스테롤 에스터라제를 특이적으로 인지하는 단세포군 항체와 이를 분비하는 융합세포주
JPH1084958A (ja)	1998-04-07	抗繊維芽細胞増殖因子６モノクローナル抗体
JPH06253886A (ja)	1994-09-13	Ｃｒｋタンパクに対するモノクローナル抗体と、この抗体を産生するハイブリドーマ株
JPH1121300A (ja)	1999-01-26	抗ヒトトランスフェリンモノクローナル抗体及びこれを産生するハイブリドーマ細胞株
JPH08231599A (ja)	1996-09-10	抗チロシナーゼモノクローナル抗体Ｆａｂフラグメント
JPH05268989A (ja)	1993-10-19	抗ヒト***γ−グルタミルトランスペプチダーゼモノクローナル抗体、ハイブリドーマおよび免疫学的検出方法
JPH05244986A (ja)	1993-09-24	モノクローナル抗体、該抗体を製造する方法及び該抗体を用いた測定方法